Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

S Nagao; P Harter; A Leary; C Cropet; S Pignata; K Fujiwara; AJG Martin; G Bogner; I Vergote; N Colombo; J Maenpaa; F Selle; B Schmalfeldt; G Scambia; EMG Alia; C Lefeuvre-Plesse; A Belau; A Lortholary; M Gropp-Meier; E Pujade-Lauraine; I Ray-Coquard

doi:10.1016/j.annonc.2022.10.212

Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

S Nagao
, P Harter
, A Leary
, C Cropet
, S Pignata
, K Fujiwara
, AJG Martin
, G Bogner
, I Vergote
, N Colombo
, J Maenpaa
, F Selle
, B Schmalfeldt
, G Scambia
, EMG Alia
, C Lefeuvre-Plesse
, A Belau
, A Lortholary
, M Gropp-Meier
, E Pujade-Lauraine

I Ray-Coquard

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

5 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	S1503-S1504
Fachzeitschrift	ANNALS OF ONCOLOGY
Jahrgang	33
DOIs	https://doi.org/10.1016/j.annonc.2022.10.212
Publikationsstatus	Veröffentlicht - 2022
Veranstaltung	ESMO Asia Congress - Singapore, SINGAPORE Dauer: 2 Dez. 2022 → 4 Dez. 2022

Zugriff auf Dokument

10.1016/j.annonc.2022.10.212

Dieses zitieren

Nagao, S., Harter, P., Leary, A., Cropet, C., Pignata, S., Fujiwara, K., Martin, AJG., Bogner, G., Vergote, I., Colombo, N., Maenpaa, J., Selle, F., Schmalfeldt, B., Scambia, G., Alia, EMG., Lefeuvre-Plesse, C., Belau, A., Lortholary, A., Gropp-Meier, M., ... Ray-Coquard, I. (2022). Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ANNALS OF ONCOLOGY , 33, S1503-S1504. https://doi.org/10.1016/j.annonc.2022.10.212

Nagao, S ; Harter, P ; Leary, A et al. / Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). in: ANNALS OF ONCOLOGY 2022 ; Jahrgang 33. S. S1503-S1504.

@article{9bfc88afcf3e4422a6bbf534893502f4,

title = "Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)",

author = "S Nagao and P Harter and A Leary and C Cropet and S Pignata and K Fujiwara and AJG Martin and G Bogner and I Vergote and N Colombo and J Maenpaa and F Selle and B Schmalfeldt and G Scambia and EMG Alia and C Lefeuvre-Plesse and A Belau and A Lortholary and M Gropp-Meier and E Pujade-Lauraine and I Ray-Coquard",

year = "2022",

doi = "10.1016/j.annonc.2022.10.212",

language = "English",

volume = "33",

pages = "S1503--S1504",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

note = "ESMO Asia Congress ; Conference date: 02-12-2022 Through 04-12-2022",

}

Nagao, S, Harter, P, Leary, A, Cropet, C, Pignata, S, Fujiwara, K, Martin, AJG, Bogner, G, Vergote, I, Colombo, N, Maenpaa, J, Selle, F, Schmalfeldt, B, Scambia, G, Alia, EMG, Lefeuvre-Plesse, C, Belau, A, Lortholary, A, Gropp-Meier, M, Pujade-Lauraine, E & Ray-Coquard, I 2022, 'Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)', ANNALS OF ONCOLOGY , Jg. 33, S. S1503-S1504. https://doi.org/10.1016/j.annonc.2022.10.212

Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). / Nagao, S; Harter, P; Leary, A et al.
in: ANNALS OF ONCOLOGY , Jahrgang 33, 2022, S. S1503-S1504.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

AU - Nagao, S

AU - Harter, P

AU - Leary, A

AU - Cropet, C

AU - Pignata, S

AU - Fujiwara, K

AU - Martin, AJG

AU - Bogner, G

AU - Vergote, I

AU - Colombo, N

AU - Maenpaa, J

AU - Selle, F

AU - Schmalfeldt, B

AU - Scambia, G

AU - Alia, EMG

AU - Lefeuvre-Plesse, C

AU - Belau, A

AU - Lortholary, A

AU - Gropp-Meier, M

AU - Pujade-Lauraine, E

AU - Ray-Coquard, I

PY - 2022

Y1 - 2022

U2 - 10.1016/j.annonc.2022.10.212

DO - 10.1016/j.annonc.2022.10.212

M3 - Abstract (Journal)

SN - 0923-7534

VL - 33

SP - S1503-S1504

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - ESMO Asia Congress

Y2 - 2 December 2022 through 4 December 2022

ER -

Nagao S, Harter P, Leary A, Cropet C, Pignata S, Fujiwara K et al. Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ANNALS OF ONCOLOGY . 2022;33:S1503-S1504. doi: 10.1016/j.annonc.2022.10.212